These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23175722)

  • 1. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?
    Antoniol C; Jilek S; Schluep M; Mercier N; Canales M; Le Goff G; Campiche C; Pantaleo G; Du Pasquier RA
    Neurology; 2012 Dec; 79(23):2258-64. PubMed ID: 23175722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?
    Zahednasab H
    Neurology; 2013 Jul; 81(1):97-8. PubMed ID: 23817518
    [No Abstract]   [Full Text] [Related]  

  • 3. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.
    Du Pasquier RA; Kuroda MJ; Zheng Y; Jean-Jacques J; Letvin NL; Koralnik IJ
    Brain; 2004 Sep; 127(Pt 9):1970-8. PubMed ID: 15215217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
    Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR
    PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection.
    Martin-Blondel G; Bauer J; Cuvinciuc V; Uro-Coste E; Debard A; Massip P; Delisle MB; Lassmann H; Marchou B; Mars LT; Liblau RS
    Neurology; 2013 Sep; 81(11):964-70. PubMed ID: 23935178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
    Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy.
    Koralnik IJ
    J Neurovirol; 2002 Dec; 8 Suppl 2():59-65. PubMed ID: 12491153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy.
    Lima MA; Marzocchetti A; Autissier P; Tompkins T; Chen Y; Gordon J; Clifford DB; Gandhi RT; Venna N; Berger JR; Koralnik IJ
    J Virol; 2007 Apr; 81(7):3361-8. PubMed ID: 17229701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
    Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
    Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.
    Rinaldi L; Rinaldi F; Perini P; Calabrese M; Seppi D; Grossi P; Mattisi I; Barzon L; Mengoli C; Sanzari M; Palú G; Gallo P
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1345-50. PubMed ID: 20547618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
    Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TCR bias and HLA cross-restriction are strategies of human brain-infiltrating JC virus-specific CD4+ T cells during viral infection.
    Yousef S; Planas R; Chakroun K; Hoffmeister-Ullerich S; Binder TM; Eiermann TH; Martin R; Sospedra M
    J Immunol; 2012 Oct; 189(7):3618-30. PubMed ID: 22942431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
    Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
    PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.
    Aly L; Yousef S; Schippling S; Jelcic I; Breiden P; Matschke J; Schulz R; Bofill-Mas S; Jones L; Demina V; Linnebank M; Ogg G; Girones R; Weber T; Sospedra M; Martin R
    Brain; 2011 Sep; 134(Pt 9):2687-702. PubMed ID: 21908874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.
    Zingaropoli MA; Iannetta M; Pontecorvo S; Anzivino E; Prezioso C; Rodio DM; Morreale M; D'Abramo A; Oliva A; Lichtner M; Cortese A; Frontoni M; Pietropaolo V; Francia A; Mastroianni CM; Vullo V; Ciardi MR
    Biomed Res Int; 2018; 2018():5297980. PubMed ID: 29682547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comment: avoiding detrimental effects of corticosteroids on JC virus T-cell responses--primum non nocere.
    Koralnik IJ; Clifford DB
    Neurology; 2012 Dec; 79(23):2263. PubMed ID: 23175725
    [No Abstract]   [Full Text] [Related]  

  • 18. Author Response.
    Du Pasquier RA; Canales M; Schluep M
    Neurology; 2013 Jul; 81(1):98. PubMed ID: 23980272
    [No Abstract]   [Full Text] [Related]  

  • 19. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
    Skarlis C; Papadopoulos V; Raftopoulou S; Mavragani CP; Evangelopoulos ME
    J Neurol Sci; 2024 Jun; 461():123046. PubMed ID: 38761670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome.
    Gheuens S; Bord E; Kesari S; Simpson DM; Gandhi RT; Clifford DB; Berger JR; Ngo L; Koralnik IJ
    J Virol; 2011 Jul; 85(14):7256-63. PubMed ID: 21543472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.